Cleerly

cleerly_compare_logo_white

Assess plaque and help guide treatment. All with one AI-powered solution.

Request a demo

why-compare-icon1-v2

Assess changes in plaque over time

Cleerly COMPARE provides longitudinal disease evaluation so providers can assess changes in CAD progression — key to heart attack prevention

why-compare-icon2-v2

Guide personalized treatment

The report from Cleerly COMPARE helps inform treatment decisions, allowing you to individualize therapy to specific patient needs

why-compare-icon3-v2

Human-refined

The AI-generated report is reviewed, refined, and confirmed by a human reviewer to ensure that you’re working with the precise, consistent analysis data

From plaque analysis to lifestyle optimization

Evaluation and monitoring of plaque, including low-density-non-calcified plaque, non-calcified plaque, and calcified plaque, can help physicians assess a patient’s risk above and beyond stenosis severity and aggregate plaque burden¹
Clinically relevant insights provide a framework for physicians to initiate, intensify, or de-intensify medical management of patients with CAD²

41%

reduction in the rate of death and non-fatal heart attacks in patients with chest pain that receive a CCTA vs patients that did not at 5 years³


Evaluate plaque volume from scan to scan	In some cases, plaque may regress between scans, indicating that the patient's therapy is effective	Analyze in lesion-by-lesion detail

AI-generated. Human-refined.

Taking the Cleerly AI-generated report further with a personalized expert reviewer. Included with the Cleerly COMPARE feature is an added level of analysis by a human reviewer. There is no extra cost for this additional level of review.